FIELD: analytical chemistry.
SUBSTANCE: disclosed is a method for quantitative determination of rivaroxaban in blood by high-performance liquid chromatography, including the sequential addition to whole blood of a sulfanilamide solution in acetonitrile, acetonitrile and activated carbon, ultrasonic treatment, centrifugation, filtration, separation on a chromatographic column filled with silica gel with grafted aminopropyl radicals with particle size of 5 mcm, with a pre-column filled with silica gel C18 with particle size 5 mcm, wherein the mobile phase used is a mixture of acetonitrile and 0.1% aqueous solution of formic acid in ratio of 85:15 vol.% in isocratic elution mode, detection is performed with the use of a diode matrix detector at wave length 254 nm, and the blood rivaroxaban concentration is determined at retention time 1.974 min.
EFFECT: invention provides detecting rivaroxaban in whole blood by high-performance liquid chromatography with efficient separation of rivaroxaban with other possible impurities present in the sample.
1 cl, 2 dwg, 3 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF QUANTIFICATION OF AMANTADINE IN BLOOD PLASMA | 2017 |
|
RU2650968C1 |
METHOD FOR DETERMINING CONTENT OF FUMARIC AND MALEIC ACIDS IN BLOOD PLASMA BY METHOD OF HIGHLY EFFECTIVE LIQUID CHROMATOGRAPHY | 2018 |
|
RU2677341C1 |
METHOD FOR DETERMINATION OF IRRITANTS IN ALCOHOL EXTRACTS BY HIGH-EFFICIENT LIQUID CHROMATOGRAPHY | 2021 |
|
RU2787962C1 |
METHOD FOR DETERMINING AMIODARONE AND ITS MAIN METABOLITE DESETHYLAMIODARONE IN HUMAN BLOOD SERUM | 2020 |
|
RU2749566C1 |
METHOD FOR DETERMINING DABIGATRAN IN HUMAN BLOOD SERUM | 2018 |
|
RU2683032C1 |
METHOD FOR DETERMINATION OF AMINOGLYCOSIDE ANTIBIOTICS BY REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY | 2022 |
|
RU2786839C1 |
METHOD FOR QUANTITATIVE DETERMINATION OF THE CONTENT OF 4-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDINE-1-OXYL IN THE AIR OF THE WORKING AREA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY | 2021 |
|
RU2756549C1 |
METHOD FOR DETERMINING LOSARTAN, ITS MAIN METABOLITE LOSARTAN CARBOXYLIC ACID AND GLIBENCLAMIDE IN HUMAN BLOOD SERUM AND URINE | 2020 |
|
RU2749567C1 |
METHOD FOR DETERMINING CEFOTAXIME BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY | 2018 |
|
RU2687493C1 |
METHOD FOR DETERMINATION OF CIPROFLOXACIN BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY | 2020 |
|
RU2751338C1 |
Authors
Dates
2025-05-14—Published
2025-03-05—Filed